A Symposium, Angiotensin-converting Enzyme Inhibition Therapy in the Treatment of Congestive Heart Failure PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download A Symposium, Angiotensin-converting Enzyme Inhibition Therapy in the Treatment of Congestive Heart Failure PDF full book. Access full book title A Symposium, Angiotensin-converting Enzyme Inhibition Therapy in the Treatment of Congestive Heart Failure by Symposium Angiotensin Converting Enzyme Inhibition Therapy in the Treatment of Congestive Heart Failure (1990, Phoenix, Ariz.). Download full books in PDF and EPUB format.
Author: Symposium Angiotensin Converting Enzyme Inhibition Therapy in the Treatment of Congestive Heart Failure (1990, Phoenix, Ariz.)
Publisher:
ISBN:
Category :
Languages : en
Pages : 45
Get Book Here
Book Description
Author: Symposium Angiotensin Converting Enzyme Inhibition Therapy in the Treatment of Congestive Heart Failure (1990, Phoenix, Ariz.)
Publisher:
ISBN:
Category :
Languages : en
Pages : 45
Get Book Here
Book Description
Author: Jay N. Cohn
Publisher:
ISBN:
Category :
Languages : en
Pages : 45
Get Book Here
Book Description
Author: Jay N. Cohn
Publisher:
ISBN:
Category :
Languages : en
Pages : 45
Get Book Here
Book Description
Author: Lionel H. Opie
Publisher:
ISBN:
Category : Angiotensin converting enzyme
Languages : en
Pages : 292
Get Book Here
Book Description
Author: Michael Böhm
Publisher: Springer Science & Business Media
ISBN: 3642603009
Category : Medical
Languages : en
Pages : 299
Get Book Here
Book Description
Arterial hypertension, coronary heart disease and heart fail ure are the commonest cardiovascular conditions to present in clinical practice. Over the past few years it has become in creasingly clear that they are closely and causally interrelated and that their relationship can have a significant bearing on prognosis. Epidemiological studies have shown that arterial hypertension is one of the most important risk factors for de veloping heart failure. Only one in four patients with hyper tension is adequately managed, and in 50% of cases, the hypertension has not been recognised or treated. Patients with pre-existing hypertension who go on to suffer an acute myocardial infarction have usually not previously had typi cal angina symptoms, the infarct territory is larger, life threatening arrhythmias are commoner and hence in-hospi tal mortality and long-term prognosis are markedly worse. The presence of raised blood pressure in the post-infarct phase doubles the risk of manifest heart failure. The close relationship between hypertension, coronary heart disease and heart failure makes the choice of therapeu tic strategy particularly important. Agents and classes of agents that have prognostic value in all three conditions should be considered first, as synergy might result in addi tional benefits. In such patients, this sort of therapeutic deci sion-making might have further advantages. The use of these agents may prevent complications which are not yet clinically obvious (such as heart failure).
Author: Pedro D'Orléans-Juste
Publisher: Birkhäuser
ISBN: 3034875797
Category : Medical
Languages : en
Pages : 192
Get Book Here
Book Description
Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions.
Author: John B. Kostis
Publisher:
ISBN:
Category : Science
Languages : en
Pages : 406
Get Book Here
Book Description
The emergence of an exciting new class of drugs known as ACE inhibitors is having a major impact on the treatment of hypertension and heart failure. This work provides the most complete and up-to-date investigation on the biochemistry, comparative pharmacology, and clinical utility of these powerful agents. Written by internationally respected authorities, sections offer state-of-the-art reviews, with special attention given to the potential of ACE inhibitors for established as well as new indications, either alone or in combination with older drugs. The broad range of topics includes the physiology of the renin-angiotensin system, the similarities and differences among ACE inhibitors, and the advantages of ACE inhibitors with respect to ?quality of life.? Furthermore, "Angiotensin Converting Enzyme Inhibitors" is the only review of the new and potentially promising ACE inhibitors under development.
Author: Gerd Heusch
Publisher: Springer Science & Business Media
ISBN: 3642724973
Category : Medical
Languages : en
Pages : 358
Get Book Here
Book Description
In the last decade, ACE inhibitors have become a cornerstone of cardiovascular drug therapy. Beneficial effects in patients with hypertension, heart failure, and post myocardial infarction have been established in large clinical trials. In parallel, ex perimental research has shifted the interest from the immediate homeostatic function of the circulating renin-angiotensin-system to the multiple paracrine functions of local tissue renin-angiotensin-systems, including hypertrophy, hyperplasia, athe- oenesis, and vasomotion. . It was the aim or a symposium held in Hamburg, October 22-24, 1992, to bring together an international panel of experimental and clinical scientists and to discuss the most recent findings on the role of angiotensin and associated mediators in car diovascular adaptation and disease, with a particular emphasis on the treatment of such disease by ACE inhibitors. The meeting and this publication were generously supported by Astra Chemicals. H. Grobecker G. Heusch B.E. Strauer Contents Foreword. ... ... V Introduction Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart Dzau, V.J. ... ... 1 Myocardial Perfusion Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone Luscher, T.F. ... ... 15 Local and neurohumoral control of coronary blood flow Krajcar, M., G. Heusch. ... 25 ACE-inhibitors in coronary artery disease? Vogt, M., W. Matz, B.E. Strauer ... 43 Myocardial Hypertrophy Molecular mechanisms of cardiac gene expression Nadal-Ginard, B., V. Mahdavi ... 65 Myocardial perfusion dependent and independent mechanisms of regional myocardial dysfunction in hypertrophy Vatner, S.F., L. Hittinger ...
Author: Lionel H. Opie
Publisher: Wiley-Liss
ISBN:
Category : Medical
Languages : en
Pages : 340
Get Book Here
Book Description
About the Book ACE inhibitors are justly regarded as the most important advance in cardiac drug therapy since the advent of calcium channel antagonist drugs. Acting basically as inhibitors of the renin-angiotensin vasoconstrictor system, these agents have grown in importance to become among the therapeutic agents first choice for hypertension and a cornerstone of therapy in congestive heart failure. Recent studies show that they can also prevent overt heart failure and reinfarction, and beneficially influence diabetic renal lesions. The major aim of Angiotensin-Converting Enzyme Inhibitors: Scientific Basis for Clinical Use is to present the clinician with the information needed for the practical and discerning use of ACE inhibitors. When do these agents really work and in what doses? Which claims are based on promotional material and which claims have relevance for the clinician in the practical treatment of hypertension, heart failure or myocardial infarction? This Second Edition adds new material that critically reviews the recent large trials including Consensus-II, Save, V-HeFT-II, Aire, and ISIS-IV and guides the clinician toward a rational policy of use. There is an important new chapter on the use of ACE inhibitors in the metabolic cardiovascular syndrome and in diabetic nephropathy. Reviews of Other Books by the Author Drugs for the Heart—"A gem" (New England Journal of Medicine) The Heart—"The subjects are brilliantly illuminated and made exciting by excellent line diagrams" (The Lancet) Reviews of First Edition of this Book "A new milestone" (British Medical Journal) "Pathophysiology is clarified by numerous diagrams in a style well-known from Opie’s former books" (The Lancet)
Author: Jeffrey K. Aronson
Publisher: Elsevier
ISBN: 0444537163
Category : Medical
Languages : en
Pages : 7629
Get Book Here
Book Description
Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Sixteenth Edition, Seven Volume Set builds on the success of the 15 previous editions, providing an extensively reorganized and expanded resource that now comprises more than 1,500 individual drug articles with the most complete coverage of adverse reactions and interactions found anywhere. Each article contains detailed and authoritative information about the adverse effects of each drug, with comprehensive references to the primary literature, making this a must–have reference work for any academic or medical library, pharmacologist, regulatory organization, hospital dispensary, or pharmaceutical company. The online version of the book provides an unparalleled depth of coverage and functionality by offering convenient desktop access and enhanced features such as increased searchability, extensive internal cross-linking, and fully downloadable and printable full-text, HTML or PDF articles. Enhanced encyclopedic format with drug monographs now organized alphabetically Completely expanded coverage of each drug, with more than 1,500 drug articles and information on adverse reactions and interactions Clearer, systematic organization of information for easier reading, including case histories to provide perspective on each listing Extensive bibliography with over 40,000 references A must–have reference work for any academic or medical library, pharmacologist, regulatory organization, hospital dispensary, or pharmaceutical company
